OCULAR THERAPEUTIX,INC. (NASDAQ:OCUL) Files An 8-K Entry into a Material Definitive Agreement

OCULAR THERAPEUTIX,INC. (NASDAQ:OCUL) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01

Story continues below

Entry into a Material Definitive Agreement.

Lease Amendment

On October10, 2017, Ocular Therapeutix,Inc. (the “Company”) and CCC Investors LLC (the “Landlord”) entered into an amendment (the “Second Amendment”) to a lease agreement for the Company’s laboratory and manufacturing space located at 34 Crosby Drive (the “34 Crosby Premises”) and 36 Crosby Drive (the “36 Crosby Premises”), each in Bedford, Massachusetts. The Second Amendment amends the original lease agreement, by and between the Company and CCC Investors LLC, as successor-in-interest to RAR2-Crosby Corporate Center QRS,Inc., dated as of September2, 2009 (as amended to date, the “Lease”).

The Second Amendment extends the term of the Lease for the 36 Crosby Premises from June30, 2018 (the “Former Termination Date”) to July31, 2023 (the “New Termination Date”). Further, the Second Amendment acknowledges that the Company has previously vacated and surrendered, and the Lease has expired with regards to, the 34 Crosby Premises, reducing the total laboratory and manufacturing space subject to the Lease to 20,445 square feet. Accordingly, the Second Amendment reduces the Company’s required security deposit under the Lease from approximately $227,539 to approximately $113,769. Under the Second Amendment, the annual base rent for the 36 Crosby Premises shall be approximately $524,329 until the Former Termination Date, shall be $0 from July1, 2018 to July31, 2018, and shall be approximately $544,041 from August1, 2018 to July31, 2019. The annual base rent shall increase annually thereafter.

The Second Amendment also provides the Company a one-time option to terminate the Lease on July31, 2021, upon the Company’s delivery to the Landlord on or before July31, 2020 of a termination notice and the payment to the Landlord of a termination fee of approximately $273,474.

The foregoing description of certain terms of the Second Amendment does not purport to be complete and is qualified in its entirety by reference to the Second Amendment, a copy of which is attached as Exhibit10.1 hereto and is incorporated herein by reference.

Item 1.01

Financial Statements and Exhibits.

(d)Exhibits.


OCULAR THERAPEUTIX, INC Exhibit
EX-10.1 2 a17-23111_1ex10d1.htm EX-10.1 Exhibit 10.1   SECOND AMENDMENT TO LEASE   THIS SECOND AMENDMENT TO LEASE (this “Amendment”) dated as of this 10th day of October,…
To view the full exhibit click here

About OCULAR THERAPEUTIX,INC. (NASDAQ:OCUL)

Ocular Therapeutix, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies for diseases and conditions of the eye using its hydrogel platform technology. The Company’s bioresorbable hydrogel based product candidates are designed to provide sustained delivery of therapeutic agents to the eye. Its hydrogel is a bioresorbable formulation of polyethylene glycol (PEG), which when constituted with water takes on a gelatinous consistency. The Company’s product pipeline includes marketed candidate ReSure Sealant and products under development, such as OTX-DP, OTX-TP, OTX-MP and anti-VEGF hydrogel depot. The Company’s lead product candidates are OTX-DP and OTX-TP. The OTX-DP product candidate incorporates the corticosteroid dexamethasone as an active pharmaceutical ingredient in its punctum plug. The OTX-TP product candidate incorporates the prostaglandin analog travoprost as an active pharmaceutical ingredient in its punctum plug.

An ad to help with our costs